ACTA1 and familial pancreatic carcinoma: Recent attempts to therapeutically target CAFs (specifically depleting αSMA+ CAFs) failed in preclinical models of pancreatic cancer and even potentially worsened patients` prognosis 88, which was, in part, due to an incomplete understanding of CAF heterogeneity.